ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer

EGFR-targeted therapy is a key treatment approach in patients with RAS wildtype metastatic colorectal cancers (CRC). Still, also RAS wildtype CRC may be resistant to EGFR-targeted therapy, with few predictive markers available for improved stratification of patients. Here, we investigated response o...

Descripción completa

Detalles Bibliográficos
Autores principales: Geißler, Anna-Lena, Geißler, Miriam, Kottmann, Daniel, Lutz, Lisa, Fichter, Christiane D., Fritsch, Ralph, Weddeling, Britta, Makowiec, Frank, Werner, Martin, Lassmann, Silke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370031/
https://www.ncbi.nlm.nih.gov/pubmed/28199979
http://dx.doi.org/10.18632/oncotarget.15211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370031/
https://www.ncbi.nlm.nih.gov/pubmed/28199979
http://dx.doi.org/10.18632/oncotarget.15211

Ejemplares similares